%PDF-1.4
%
59 0 obj
<>
endobj
56 0 obj
<>
endobj
123 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-06-09T09:44:25Z
2024-03-28T15:30:11-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T15:30:11-07:00
application/pdf
Heather
2003-647.july
uuid:e2001dd2-1dd1-11b2-0a00-0c0927fd5800
uuid:e2001dd4-1dd1-11b2-0a00-6a0000000000
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>
endobj
60 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
149 0 obj
[154 0 R]
endobj
150 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.1227 Tw 10 0 0 10 54 713.1616 Tm
(confirmation is not always carried out, given the program)Tj
0.0948 Tw 0 -1.22 TD
[(priorities and constraints. )18 (W)80 (e believe that the conservative)]TJ
0.258 Tw T*
(definition of attrition we used is clinically relevant and)Tj
0.1532 Tw T*
[(useful. )18 (While it can be ar)18 (gued that more complex defini-)]TJ
-0.013 Tw T*
(tions, such as missing 2 or more consecutive questionnaires,)Tj
0.036 Tw T*
(should be used, we believe that those are unlikely to add to)Tj
0.19141 Tw T*
(our analyses. Until methodological research establishes a)Tj
0.19189 Tw T*
(more satisfactory way to define attrition, we recommend)Tj
0.02499 Tw T*
(that our simple definition be used.)Tj
0.0787 Tw 1.2 -1.2 Td
[(Secondly)65 (, loss of study subjects due to death is a major)]TJ
-0.0239 Tw -1.2 -1.2 Td
[(issue, as the incidence of RA)-171 (increases with age and because)]TJ
0.2168 Tw 0 -1.2 TD
[(RA)-412 (is associated with increased mortality)65 (. In calculating)]TJ
0.12959 Tw T*
(attrition rates, we censored the observations of those who)Tj
0.14799 Tw T*
(died; in doing so, the calculated rates of attrition may be)Tj
0.1839 Tw T*
[(underestimated. However)40 (, mortality itself is an important)]TJ
0.02499 Tw T*
(outcome and is not necessarily a loss to longterm studies.)Tj
0.15109 Tw 1.2 -1.2 Td
(Our results have implications for our understanding of)Tj
0.0688 Tw -1.2 -1.2 Td
(the validity of followup studies being reported, and for the)Tj
0.2032 Tw T*
[(design of better followup studies in the future. )18 (W)80 (e have)]TJ
0.0527 Tw T*
(provided the evidence that followup studies can potentially)Tj
0.0244 Tw T*
[(be biased due to selective loss of subjects who are younger)40 (,)]TJ
0.3121 Tw T*
(are non-Caucasian, and are from poorer socioeconomic)Tj
0.043 Tw T*
(background. Strategies like oversampling a high-risk group)Tj
0.1861 Tw T*
(may easily be used to minimize such bias. Measures for)Tj
0.0199 Tc 0.8421 Tw T*
(reducing attrition are available and should be)Tj
-0.00011 Tc 0 Tw T*
(utilized)Tj
0 Tc 6.5 0 0 6.5 83.9902 414.8617 Tm
(1,10,26,27)Tj
-0.00011 Tc 0.2791 Tw 10 0 0 10 111.615 411.5616 Tm
[(. )18 (W)80 (e believe that all databanks should be)]TJ
0.13989 Tw -5.7615 -1.2 Td
(required to report their attrition pattern so that the results)Tj
0.01089 Tw T*
[(they report can be interpreted correctly)65 (. Sensitivity analyses)]TJ
0.00841 Tw T*
[(to assess the ef)18 (fect of attrition on inferences about the study)]TJ
0.02499 Tw T*
(subjects also needs to be mandatory)Tj
0 Tc 0 Tw 6.5 0 0 6.5 198.8121 366.8617 Tm
(28)Tj
10 0 0 10 205.312 363.5616 Tm
(.)Tj
/T1_2 1 Tf
-0.00011 Tc -15.1312 -2.4 Td
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 329.5616 Tm
[(1.)-875 (Krishnan E, Fries JF)80 (. Measuring ef)18 (fectiveness of drugs in )]TJ
1.675 -1.25 Td
[(observational databanks: promises and perils. )55 (Arthritis Res )18 (Ther)]TJ
0 Tw 0 -1.25 TD
(2004;6:41-4.)Tj
0.02499 Tw -1.675 -1.25 Td
[(2.)-875 (Fries JF)80 (. )18 (The chronic disease data bank: first principles to future)]TJ
1.675 -1.25 Td
(directions. J Med Philos 1984;9:161-80.)Tj
-1.675 -1.2375 Td
[(3.)-875 (Krishnan E, Singh G, )18 (T)35 (ugwell P)111 (. Long-term observational studies.)]TJ
1.675 -1.2375 Td
[(In: Smolen J, Lipsky P)111 (, editors. )18 (T)70 (ar)18 (geted therapies in rheumatology)65 (.)]TJ
0 -1.2375 TD
(London: Martin Dunitz; 2003.)Tj
-1.675 -1.25 Td
[(4.)-875 (W)80 (olfe F)80 (, Lassere M, van der Heijde D, et al. Preliminary core set of)]TJ
1.675 -1.25 Td
(domains and reporting requirements for longitudinal observational)Tj
0 -1.25 TD
[(studies in rheumatology)65 (. J Rheumatol 1999;26:484-9.)]TJ
-1.675 -1.25 Td
[(5.)-875 (T)70 (ouloumi G, Babiker )55 (AG, Pocock SJ, Darbyshire JH. Impact of)]TJ
1.675 -1.25 Td
(missing data due to drop-outs on estimators for rates of change in)Tj
T*
[(longitudinal studies: a simulation study)65 (. Stat Med 2001;20:3715-28.)]TJ
-1.675 -1.25 Td
[(6.)-875 (Reisine S, Fifield J, )18 (W)40 (inkelman DK. Characteristics of rheumatoid)]TJ
1.675 -1.25 Td
(arthritis patients: who participates in long-term research and who)Tj
T*
[(drops out? )55 (Arthritis Care Res 2000;13:3-10.)]TJ
-1.675 -1.25 Td
[(7.)-1132 (The National Death Index \(NDI\): National Center for Health)]TJ
1.675 -1.25 Td
[(Statistics. [Cited March 4, 2004] )55 (A)74 (vailable from:)]TJ
0 Tw T*
[(http://www)65 (.cdc.gov/nchs/r&d/ndi/ndi.htm)]TJ
0.02499 Tw -1.675 -1.2625 Td
[(8.)-875 (Singh G. )55 (Arthritis, Rheumatism and )55 (Aging Medical Information)]TJ
1.675 -1.2625 Td
(System Post-Marketing Surveillance Program. J Rheumatol)Tj
0 Tc 0 Tw 0 -1.2625 TD
[(2001;28:1)37 (174-9.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.2625 Td
[(9.)-875 (Daglish GM. Random House )18 (W)80 (ebster)-37 (\325)55 (s dictionary of )55 (American)]TJ
1.675 -1.2625 Td
[(English. New )37 (Y)100 (ork: Random House; 1997:46.)]TJ
30.825 78.146 Td
[(10.)-875 (Ribisl K, )18 (W)80 (alton )18 (W)92 (, Mowbray C, Luke D, Davidson )18 (W)92 (,)]TJ
2.175 -1.2625 Td
(Bootsmiller B. Minimizing participant attrition in panel studies)Tj
T*
[(through the use of ef)18 (fective retention and tracking strategies:)]TJ
T*
(review and recommendations. Evaluation and Program Planning)Tj
0 Tc 0 Tw T*
(1996;19:1-25.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.2625 Td
[(1)37 (1.)-875 (Clayton D, Hills M. Statistical models in epidemiology)65 (. Oxford,)]TJ
2.1381 -1.2625 Td
(UK: Oxford University Press; 1993.)Tj
-2.175 -1.2625 Td
[(12.)-875 (Gould )18 (W)92 (. Jackknife estimation. Stata )18 (T)70 (echnical Bulletin)]TJ
0 Tc 0 Tw 2.175 -1.2625 Td
(1995;24:25-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2625 Td
[(13.)-875 (Peto R, Lee P)111 (. )18 (W)80 (eibull regressions for continuous-carcinogenesis)]TJ
2.175 -1.2625 Td
(experiments. Biometrics 1973;29:457-70.)Tj
-2.175 -1.2625 Td
[(14.)-875 (Idler EL, Russell LB, Davis D. Survival, functional limitations, and)]TJ
2.175 -1.2625 Td
[(self-rated health in the NHANES I Epidemiologic Follow-up Study)65 (,)]TJ
T*
[(1992. First National Health and Nutrition Examination Survey)65 (. )55 (Am)]TJ
T*
(J Epidemiol 2000;152:874-83.)Tj
-2.175 -1.2625 Td
[(15.)-875 (Russell C, Palmer JR, )55 (Adams-Campbell LL, Rosenber)18 (g L. )]TJ
2.175 -1.2625 Td
[(Follow-up of a lar)18 (ge cohort of Black women. )55 (Am J Epidemiol)]TJ
0 Tc 0 Tw T*
(2001;154:845-53.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2625 Td
[(16.)-875 (Dudley J, Jin S, Hoover D, Metz S, )18 (Thackeray R, Chmiel J. )18 (The)]TJ
2.175 -1.2625 Td
[(Multicenter )55 (AIDS Cohort Study: retention after 9 1/2 years. )55 (Am )]TJ
T*
(J Epidemiol 1995;142:323-30.)Tj
-2.175 -1.2625 Td
[(17.)-875 (Hessol NA, Schneider M, Greenblatt RM, et al. Retention of)]TJ
2.175 -1.2625 Td
(women enrolled in a prospective study of human )Tj
T*
(immunodeficiency virus infection: impact of race, unstable)Tj
T*
[(housing, and use of human immunodeficiency virus therapy)65 (. )55 (Am )]TJ
T*
(J Epidemiol 2001;154:563-73.)Tj
-2.175 -1.25 Td
[(18.)-875 (Streib GF)80 (. Participants and drop-outs in a longitudinal study)65 (. )]TJ
2.175 -1.25 Td
(J Gerontol 1966;21:200-9.)Tj
-2.175 -1.25 Td
[(19.)-875 (Farmer ME, Locke BZ, Moscicki EK, Dannenber)18 (g )55 (AL, Larson DB,)]TJ
2.175 -1.25 Td
[(Radlof)18 (f LS. Physical activity and depressive symptoms: the)]TJ
0 -1.25 TD
[(NHANES I Epidemiologic Follow-up Study)65 (. )55 (Am J Epidemiol)]TJ
0 Tc 0 Tw T*
(1988;128:1340-51.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875 (Eaton )18 (WW)92 (, )55 (Anthony JC, )18 (T)70 (epper S, Dryman )55 (A. Psychopathology)]TJ
2.175 -1.25 Td
[(and attrition in the epidemiologic catchment area surveys. )55 (Am )]TJ
T*
(J Epidemiol 1992;135:1051-9.)Tj
-2.175 -1.25 Td
[(21.)-875 (de Graaf R, Bijl R)80 (V)129 (, Smit F)80 (, Ravelli )55 (A, )18 (V)129 (olleber)18 (gh )18 (W)111 (A. Psychiatric)]TJ
2.175 -1.25 Td
(and sociodemographic predictors of attrition in a longitudinal)Tj
T*
[(study: )18 (The Netherlands Mental Health Survey and Incidence Study)]TJ
T*
[(\(NEMESIS\). )55 (Am J Epidemiol 2000;152:1039-47.)]TJ
-2.175 -1.25 Td
[(22.)-875 (Sokka )18 (T)74 (, Kautiainen H, Mottonen )18 (T)74 (, Hannonen P)111 (. )18 (W)80 (ork disability)]TJ
2.175 -1.25 Td
(in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol)Tj
0 Tc 0 Tw T*
(1999;26:1681-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875 (W)80 (olfe F)80 (, Mitchell DM, Sibley JT)74 (, et al. )18 (The mortality of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis. )55 (Arthritis Rheum 1994;37:481-94.)]TJ
-2.175 -1.25 Td
[(24.)-875 (Criqui MH, Barrett-Connor E, )55 (Austin M. Dif)18 (ferences between)]TJ
2.175 -1.25 Td
(respondents and non-respondents in a population-based )Tj
T*
[(cardiovascular disease study)65 (. )55 (Am J Epidemiol 1978;108:367-72.)]TJ
-2.175 -1.25 Td
[(25.)-875 (Kaslow RA, Ostrow DG, Detels R, Phair JP)111 (, Polk BF)80 (, Rinaldo CR)]TJ
2.175 -1.25 Td
[(Jr)55 (. )18 (The Multicenter )55 (AIDS Cohort Study: rationale, or)18 (ganization, and)]TJ
T*
[(selected characteristics of the participants. )55 (Am J Epidemiol)]TJ
0 Tc 0 Tw T*
(1987;126:310-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875 (Leigh JP)111 (, )18 (W)80 (ard MM, Fries JF)80 (. Reducing attrition bias with an)]TJ
2.175 -1.25 Td
(instrumental variable in a regression model: results from a panel of)Tj
T*
(rheumatoid arthritis patients. Stat Med 1993;12:1005-18.)Tj
-2.175 -1.25 Td
[(27.)-875 (Kessler RC, Little RJ, Groves RM. )55 (Advances in strategies for )]TJ
2.175 -1.25 Td
(minimizing and adjusting for survey nonresponse. Epidemiol Rev)Tj
0 Tc 0 Tw T*
(1995;17:192-204.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875 (T)70 (ouloumi G, Pocock SJ, Babiker )55 (AG, Darbyshire JH. Impact of)]TJ
2.175 -1.25 Td
(missing data due to selective dropouts in cohort studies and clinical)Tj
T*
(trials. Epidemiology 2002;13:347-55.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:7)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1326)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_4 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
39 0 obj
<>stream
8;Z\6Mf&VO#g<8J+MT_7$+@AhQUdfGPKKb;]l@Gq3&1^4C^hQtr1a]Mh56].GoQ7Wm&X&6?]CO)n&3(GdR+kBWI
>Z7kgY*'3eK1Bp,Ku:XNe9K1e.Wb;B9h[uZMRm6'&u%ZqRr$uVV/;)ISh$1BN.m#H
,ffRqlc6hpV5/NgHH]n]`%ONQ<;6r98bm,9@B;CNrf>g<`Wut8G:!q9YqFJKG^hkH
s''Y$U]"g_a1$"3p.UHVTr;$:q"9pG_/GPf;$nAS\J?CE#Wd*_(_ark<[4b]b@?33
T,T9VkpLV8YX_s-3L\1;&Ere3,?C5gTqnX;/j/&a*5q/0aRsr3Q3+$KXSV=tK$>3];
]`>B(a).SZ3\F)n?.f+RD#PUr<1e2??DpF/[MF\W%2#nh.WKIWEgMT^f3(k/0a!4X
r19>,L`Dn.;:YiU8?OuXAuG,OCFp?\NP5!m5RVJe*9EorWlZK3NPb*g6GqAKDGq*A
l'h0nJFd+C$Ojo'i#Z@$5I(s7aFaJ7_C06)L4;`*1Hs'A7#e5\lP-!^%$.S"H6mlu
@*5So>Si1)%>4=^;c;%bLaQ=Y5Dk5sLmiPp]/\N0a$mM:CDU$oh4lM:q[70s1!+=B7+9~>
endstream
endobj
43 0 obj
[/Indexed/DeviceRGB 255 42 0 R]
endobj
42 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
98 0 obj
<>
endobj
66 0 obj
<>
endobj
24 0 obj
<>
endobj
62 0 obj
<>
endobj
83 0 obj
<>
endobj
128 0 obj
<>
endobj
63 0 obj
<>
endobj
75 0 obj
<>stream
H{PSw&E^-FEY|"I!J$@H yQ@T瞧VkvM?;:39wΜ9q06-HŊ[Tɾw7lK|%9wGg<ҷwy/σ33sϘF8U~ҥ˄K$KW%)Jf1V~]ޮf6$LJK̖}2yL.R!5y`bXe(R # ɔt1!%--O$IDrX_Ծ|`38##&$a),|&6:H/ J-AV&R@n=/=IM؇rq:p\xOVD`Y9)
..]\UӡLYfig'uÛm k1>sµΔ
I[45)ZU~QY}BYȖ*r5yz$Ϡ1y(' -G&QNGN{^I9LvA|^@ХcZ^UHZ(q :i*rGuQ6%kG!чTBis7n
|^? ˣaއQFel)Nh9l4d2_Ae[|fcS>FhN#A Y}W/솠e)8~<ȄP=?\^sF ]T䂮6rVt6=~F MVa6~zYІ]L*-UGe|?L]y)yฉ_~xȡ?AWѯq$?nS6(>.|V3xą;/Y#@juP~ncȄ>Ph'`pyB@8#6[Z:QhãSՅI(JrS ﮒ"bILbDS,_]ϴT=omIaTjE%i555zX `9[XAق[ tWߨ2170in@w@O|r<M}ZUEr%nXUȑ9k[8UT);PQܓ8}kR[)xEtdWG/&$ǹջ$)(nz o`ՍNf7o\%cb:24jyʵrcI{)
M=G[LPoPPijW}#vU/IN^jr:"i#;w{&|vw͆ rY>u*j>W`f_8L8͏Gg\EX}>#'=rl+,vw2I^>6oQgSeSij>+ XKl ANGE|_-Et,}_<l`#颔ƒFy!C)
A$Cy7k8T;#ۿTݐ* WA UH.ow|-G1~m1g>PpE=RD{ࡃ -4a?!RSV!7CcO7 $;>h>Ԯ9,cQ|"#ҕ:݁Ҝ⚴)mr0ᬳ`]+iPU6ԅxfHB&#h[۟}x@7}M"z HiQ{("ٺVtq?7]AImEx
!ʣpc|Il-G89À9.ZjU
d
H ! [ad3,JU0p:}3/X23ιw~w/jrjy#[o
su٧Yt]bum{2Ь4~R ~FvE]"@a O{f\Un-Pt;M7'h?=9oHL"c#-윐M\H.,&ߠ* I;xUqJ,9ѵoU¬z{3ԃfFjY ָWy-2x];k>\]^e§I*F&n͎hn}jVWNTgjQb$&-@$VO'`gh!IءCW5G=$yl*c=W:;a'9Q7e'f
~f+I4;
i
@CpGg7Gݩ%q롅ugl_=ҋrX'Ntٯ!V1ޡ* beGt.8 9GCY!
Z vG'BL%b6@p1h~a2"~+gjd00r`:.(3dW( 6зߢ,XtŤ9Fc&(>떽F1lR"O-٤^wJ"Mg~j
s3fALJtCibE3HBqNZt;\v(.&Kji@5)*kƄh0
(9lq9w#9\,D#+*m[ Iյ2WrߦR)gHQ#ʑbmw0N5g@HXCMm=5@a2
b|CE2 pd)VS'nWj?
oa;dnޗ~>j`&|taRު";_`^klw GTec.mnvm~xaJ-<(kWmY=lQ\Sк`8ޟ5֯qՁa}~-G18BC2UWZϸZ-r@(!M0#g
ݵ*&sڶnEX~y=80\,Iw +"<ٞ,#ͰK
ZV7 ˆA<2r~{qeΪ犯4
4QUr]Z^>E*LKɗKR5^QSJjD:!Gbi rDsZZYQ^C6(R6/Դ6]89Mf/j8Q߿4suGK]N}Q <~ɩ氕x)jX*eELR/
MxmpD lX ,X}W>şX6p YTfHtp`(=Eh9%/ 51
{"x5uQb,jn@fu]n[Vײ;NUPA4$! q!@ P|P:ݶnwvv]cwu;w99;k2`6p \|~k#S͞}j! 's
҈L@1v@:qwGJLUr4nji=/al&-gbs }V#}]P\bK,VW2pXb
H%ch_[Us\k8jFR.
'b1D|ӂ1ʆ=ï_R,H*קc1qEJ4+dIU
hxh^a[Wܸ$8A.Wk+!y)Po]/)eSIt嗽tK<z\.%q[$0&taXyx{vC.W"*&5Hcj2u2I|0`qv \T{?Cb:N<v)`&k&Xo)MnK-F%s/DO%Bdx[uF,!6A;fhe# Ayυu^g\}ũ*9ĪԮ)0X6H0vÔxDž;zԅ- |%&)&ڟS2avM>EQ!3 ʏfyO7smNhA4eORՏOxD XEbc(( rJ)o 3oH/d7Lc0
w`\\0`xoSۘޒK_ߚ@{&7ZyRnY+穇_ie6JpDAtOl^nLQו֑Ɂ~[ A1
dWYvȉ[}
{%ʺ*